Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passion is putting a narrative to financial data. Working with teams that include senior editors, investment strategists, marketing managers, data analysts, and executives, I contribute ideas to help make content relevant, accessible, and measurable. Having ...

Not for promotional use Q4 2025 EARNINGS CALL ELI LILLY AND COMPANY Agenda Introduction and Key Events Dave Ricks, Chair and Chief Executive Officer Q4 2025 Financial Results & 2026 Financial Guidance Lucas Montarce, Chief Financial Officer R&D Update Dan Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer Question & Answer Session 3 2025 Q4 EARNINGS Safe Harbor Provision and Other Information This presentation contains forward-looking statements that are based on management's current expectations ...

Group 1: International Investment Landscape - The current dollar weakness is a significant driver affecting international investments, with corporate governance changes leading to the breakup of large conglomerates into smaller, more shareholder-friendly entities [2] - International investors are facing challenges as the traditional hedge of dollar exposure is no longer guaranteed, prompting a reevaluation of investment strategies [3][4] - There is a growing interest in U.S. private markets among international investors, indicating a shift from traditional public equity investments [4] Group 2: Market Performance and Company Updates - Uber's shares have dropped significantly following disappointing fourth-quarter results, highlighting volatility in the ridesharing sector [6] - Eli Lilly forecasts a strong year for sales driven by demand for their weight loss drug, despite warning of a potential double-digit sales drop this year [7] - Netflix is defending its merger with Warner Bros. Discovery, arguing that it will enhance content availability for consumers, although the deal is under DOJ review [8]

Eli Lilly reported stronger-than-expected fourth-quarter earnings and issued robust guidance for the coming year, as soaring demand for its GLP-1 drugs reaffirmed its dominance in the global weight-lo... ...

Core Viewpoint - Soitec is entering a new phase of development with a leadership transition, having successfully diversified into new growth areas and maintained operational excellence and cash generation [3][4]. Group 1: Leadership Transition - The current CEO, Pierre Barnabe, will step down in under two months, with Laurent Remont set to take over [3]. Group 2: Company Performance - Soitec has stabilized and diversified into new growth areas, supported by targeted investments in R&D [3]. - The company is focused on operational excellence and cash generation, backed by a healthy balance sheet [4].

分组1 - Eli Lilly reported a strong 4Q25 performance with a non-GAAP EPS of $7.54, exceeding consensus estimates by approximately $0.61 [1] - Revenue for the quarter reached $19.29 billion, reflecting a year-over-year increase of about 42.6% and surpassing expectations [1] 分组2 - The focus of the analysis is on identifying promising biotechnology companies that innovate through unique mechanisms of action, first-in-class therapies, or platform technologies [1] - The approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]

Core Insights - Eli Lilly (LLY) reported quarterly earnings of $7.54 per share, exceeding the Zacks Consensus Estimate of $6.99 per share, and up from $5.32 per share a year ago, representing an earnings surprise of +7.88% [1] - The company posted revenues of $19.29 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 7.95%, compared to $13.53 billion in the same quarter last year [2] - Lilly has surpassed consensus EPS estimates three times over the last four quarters and topped revenue estimates four times during the same period [2] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the earnings outlook for the coming quarters [3][4] - The current consensus EPS estimate for the next quarter is $6.96 on revenues of $16.75 billion, and for the current fiscal year, it is $33.24 on revenues of $77.52 billion [7] - The estimate revisions trend for Lilly was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Large Cap Pharmaceuticals industry, to which Lilly belongs, is currently in the bottom 22% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Lilly's stock may also be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Eli Lilly and Co. reported better-than-expected Q4 earnings and provided optimistic fiscal 2026 guidance, leading to a rise in stock price [1][7] Earnings Overview - Adjusted earnings for Q4 were $7.54 per share, surpassing the consensus estimate of $6.67 [2] - Total sales reached $19.3 billion, exceeding the consensus of $17.96 billion, with a year-over-year increase of 43% driven by a 46% rise in volume, partially offset by a 5% decrease from lower realized prices [2] Gross Profit and Margin - Gross profit increased by 43% to $15.9 billion, with a gross margin of 82.5%, up by 0.3 percentage points [3] - The increase in gross margin was mainly due to a favorable product mix and improved production costs, despite the impact of lower realized prices [3] Weight Loss Drugs - Revenue from key products grew to $13.8 billion in Q4 2025, primarily driven by Mounjaro and Zepbound [4] - Mounjaro's revenue surged by 110% to $7.4 billion, with U.S. revenue at $4.1 billion (up 57%) and international revenue increasing to $3.3 billion from $899 million a year ago [4] - Zepbound's U.S. revenue rose by 122% to $4.2 billion, also driven by increased demand [5] - Verzenio, a breast cancer drug, saw a 3% revenue increase to $1.6 billion, attributed to volume growth [5] Future Investments - The company plans to invest over $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, which will focus on next-generation weight-loss therapies [5][6] Guidance - For fiscal 2026, Eli Lilly projects adjusted earnings of $33.50-$35 per share, compared to the consensus of $33.23 [7] - Expected sales are between $80 billion and $83 billion, exceeding Wall Street's estimate of $77.62 billion [7] - Eli Lilly's stock rose by 8.85% to $1092.23 during premarket trading, nearing its 52-week high of $1133.95 [7]

Group 1 - Eli Lilly reported higher fourth-quarter profit driven by increased demand for its GLP-1 weight-loss drugs [1]

Lilly says Mounjaro and Zepbound sales more than doubled as stock rallies - MarketWatch# Lilly says Mounjaro and Zepbound sales more than doubled as stock rallies## The drugmaker also detailed strong growth for 2026Last Updated: Feb. 4, 2026 at 7:32 a.m. ETFirst Published: Feb. 4, 2026 at 7:21 a.m. ETShareResize--- Listen(3 min)Eli Lilly said its fourth-quarter sales grew by 43% to $19.3 billion, surpassing the FactSet estimate of $17.9 billion. Photo: Getty ImagesEli Lilly's stock soared 7% in premarket tr ...